ProNAi Therapeutics Inc. (NASDAQ:DNAI) has been assigned an average broker rating score of 3.00 (Hold) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a hold rating. ProNAi Therapeutics’ rating score has declined by 20% from 90 days ago as a result of a number of analysts’ ratings changes.
Brokers have set a one year consensus target price of $2.50 for the company and are predicting that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also assigned ProNAi Therapeutics an industry rank of 107 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research upgraded shares of ProNAi Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Tuesday.
Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in ProNAi Therapeutics by 16.2% in the first quarter. Renaissance Technologies LLC now owns 45,300 shares of the company’s stock worth $305,000 after buying an additional 6,300 shares during the last quarter. BlackRock Fund Advisors increased its stake in ProNAi Therapeutics by 1.8% in the second quarter. BlackRock Fund Advisors now owns 396,221 shares of the company’s stock worth $788,000 after buying an additional 7,146 shares during the last quarter. Greenleaf Trust increased its stake in ProNAi Therapeutics by 7.8% in the second quarter. Greenleaf Trust now owns 207,450 shares of the company’s stock worth $413,000 after buying an additional 14,956 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in ProNAi Therapeutics by 4.6% in the second quarter. PNC Financial Services Group Inc. now owns 601,092 shares of the company’s stock worth $1,197,000 after buying an additional 26,226 shares during the last quarter. Finally, Bridgeway Capital Management Inc. bought a new stake in ProNAi Therapeutics during the second quarter worth about $109,000. Institutional investors own 35.25% of the company’s stock.
Shares of ProNAi Therapeutics (NASDAQ:DNAI) traded down 1.62% during mid-day trading on Thursday, reaching $1.82. 561,899 shares of the company were exchanged. The firm’s 50-day moving average is $1.85 and its 200-day moving average is $3.36. ProNAi Therapeutics has a 12 month low of $1.77 and a 12 month high of $20.85. The company’s market capitalization is $55.19 million.
ProNAi Therapeutics (NASDAQ:DNAI) last issued its quarterly earnings results on Friday, August 12th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.05. On average, equities analysts forecast that ProNAi Therapeutics will post ($1.32) earnings per share for the current fiscal year.
ProNAi Therapeutics Company Profile
ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.